Sen. Grassley Wants "Independent" Drug Safety Function In FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee chairman urges structural change at FDA during hearing on Merck's withdrawn COX-2 inhibitor Vioxx. Ranking Democrat Baucus says idea "makes sense;" FDA's Kweder tells the committee she personally has no objection to an independent safety office.
You may also be interested in...
Crawford Nomination To Be FDA Commissioner Clears Senate 78-16
Three Republicans, 13 Democrats vote against the acting commissioner. Finance Committee chair Grassley says that Crawford “has not stepped up to the plate” to address systemic problems at FDA.
Crawford Nomination To Be FDA Commissioner Clears Senate 78-16
Three Republicans, 13 Democrats vote against the acting commissioner. Finance Committee chair Grassley says that Crawford “has not stepped up to the plate” to address systemic problems at FDA.
Office Of New Drugs' Oversight Creates Advisory Committee Bias – FDA’s Graham
OND’s role in appointing advisory committee members and deciding what issues receive attention leads to a “pro-drug bias and regulatory conflicts of interest,” Office of Drug Safety’s Graham says. FDA “whistleblower” also criticizes disclosure policies for advisory committee members.